Compare · Nootropic peptide
Cerebrolysin vs Dihexa
Both are nootropic peptide compounds. Here's how they line up on the evidence — graded the same way.
| Cerebrolysin | Dihexa | |
|---|---|---|
| Evidence | Preliminary human | Animal only |
| Class | Nootropic peptide | Nootropic peptide |
| Summary | Cerebrolysin has more human trial data than most research peptides, yet its largest rigorous stroke trial was neutral and independent reviews find little benefit. | An angiotensin IV-derived oligopeptide studied in animals for synaptogenesis and cognition; it has never been tested in humans, and its foundational mechanism paper was retracted in 2025. |
| Full profile → | Full profile → |
Cerebrolysin
Cerebrolysin is one of the more genuinely studied compounds in the "nootropic peptide" category. Unlike most research peptides, it has a real prescription history abroad, multiple randomized controlled trials, and several Cochrane systematic reviews. That sounds promising until you look at what…
Dihexa
Dihexa is a small angiotensin IV-derived peptide that drew attention for animal data on dendritic spine growth and learning, plus an eye-catching claim that it is many orders of magnitude more potent than BDNF. It is sold online as a nootropic, but the honest picture is far more cautious than the…